The UK Competition Authority issues a statement of objections to three pharmaceutical companies over pay-for-delay agreements (Aspen / Amilco / Tiofarma)

Eijssen, Piet-Hein; Willis, Peter

Previous article The EU Court of Justice clarifies that when patent settlement agreements restrict a generic pharmaceutical company’s ability to enter the market they infringe EU antitrust rules (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma) Next article The US FTC reverses Administrative Law Judge decision, finding Section 5 violation for reverse-payment settlement (Endo / Impax)

3 Oct 2019

The UK Competition Authority issues a statement of objections to three pharmaceutical companies over pay-for-delay agreements (Aspen / Amilco / Tiofarma)

KEYWORDS

Reference

UK Competition Authority, Aspen / Amilco / Tiofarma, Press Release, 3 October 2019

On 3 October 2019 the Competition and Markets Authority (CMA) issued a Statement of Objections (the “SO”) to three pharmaceutical companies over pay-for-delay agreements in the market for Addison's disease treatment. In its SO the CMA sets out

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Piet-Hein Eijssen
KPN (Amsterdam)

Netherlands 33 contributions 6827 visits
Peter Willis
Bird & Bird (London)

United Kingdom 28 contributions 3136 visits

Quotation

Piet-Hein Eijssen, Peter Willis, The UK Competition Authority issues a statement of objections to three pharmaceutical companies over pay-for-delay agreements (Aspen / Amilco / Tiofarma), 3 October 2019, e-Competitions Pay-for-delay agreements, Art. N° 94004

Visites 94